vs
Ceribell, Inc.（CBLL）与CapsoVision, Inc（CV）财务数据对比。点击上方公司名可切换其他公司
Ceribell, Inc.的季度营收约是CapsoVision, Inc的7.0倍（$24.8M vs $3.5M）。Ceribell, Inc.净利率更高（-54.6% vs -223.9%，领先169.3%）。CapsoVision, Inc自由现金流更多（$-5.7M vs $-11.0M）
Ceribell, Inc.是一家专注于神经诊断领域的医疗科技企业，主打便携式快速脑电图检测设备，可为急症、重症护理场景提供便捷的癫痫发作监测解决方案，核心市场覆盖北美地区，目前正逐步推进全球化业务布局。
CapsoVision, Inc.是一家医疗科技企业，专注研发、生产先进胶囊内窥镜系统及配套诊断解决方案，旗下非侵入式胃肠道成像产品供应全球多地的医院、消化科诊所及医疗专业人员，助力提升消化道疾病检测准确率与患者诊疗体验。
CBLL vs CV — 直观对比
营收规模更大
CBLL
是对方的7.0倍
$3.5M
净利率更高
CBLL
高出169.3%
-223.9%
自由现金流更多
CV
多$5.3M
$-11.0M
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $24.8M | $3.5M |
| 净利润 | $-13.5M | $-7.9M |
| 毛利率 | 87.3% | 54.1% |
| 营业利润率 | -58.9% | -226.7% |
| 净利率 | -54.6% | -223.9% |
| 营收同比 | — | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.35 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CBLLCV
| Q4 25 | $24.8M | — | ||
| Q3 25 | $22.6M | $3.5M | ||
| Q2 25 | $21.2M | $3.3M | ||
| Q1 25 | $20.5M | — | ||
| Q3 24 | $17.2M | — |
净利润CBLLCV
| Q4 25 | $-13.5M | — | ||
| Q3 25 | $-13.5M | $-7.9M | ||
| Q2 25 | $-13.6M | $-4.6M | ||
| Q1 25 | $-12.8M | — | ||
| Q3 24 | $-10.4M | — |
毛利率CBLLCV
| Q4 25 | 87.3% | — | ||
| Q3 25 | 88.3% | 54.1% | ||
| Q2 25 | 88.1% | 54.6% | ||
| Q1 25 | 87.9% | — | ||
| Q3 24 | 87.3% | — |
营业利润率CBLLCV
| Q4 25 | -58.9% | — | ||
| Q3 25 | -64.8% | -226.7% | ||
| Q2 25 | -70.5% | -140.3% | ||
| Q1 25 | -69.3% | — | ||
| Q3 24 | -57.8% | — |
净利率CBLLCV
| Q4 25 | -54.6% | — | ||
| Q3 25 | -59.6% | -223.9% | ||
| Q2 25 | -64.4% | -139.5% | ||
| Q1 25 | -62.4% | — | ||
| Q3 24 | -60.6% | — |
每股收益（稀释后）CBLLCV
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.37 | $-0.17 | ||
| Q2 25 | $-0.38 | $-2.02 | ||
| Q1 25 | $-0.36 | — | ||
| Q3 24 | $-1.85 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $159.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $155.3M | $20.4M |
| 总资产 | $195.8M | $25.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CBLLCV
| Q4 25 | $159.3M | — | ||
| Q3 25 | $168.5M | — | ||
| Q2 25 | $177.4M | — | ||
| Q1 25 | $182.7M | — | ||
| Q3 24 | $14.1M | — |
股东权益CBLLCV
| Q4 25 | $155.3M | — | ||
| Q3 25 | $164.1M | $20.4M | ||
| Q2 25 | $172.2M | $-139.0M | ||
| Q1 25 | $180.9M | — | ||
| Q3 24 | $-136.0M | — |
总资产CBLLCV
| Q4 25 | $195.8M | — | ||
| Q3 25 | $199.5M | $25.7M | ||
| Q2 25 | $207.7M | $9.5M | ||
| Q1 25 | $213.5M | — | ||
| Q3 24 | $47.1M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-10.8M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $-11.0M | $-5.7M |
| 自由现金流率自由现金流/营收 | -44.2% | -160.5% |
| 资本支出强度资本支出/营收 | 0.7% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-41.6M | — |
8季度趋势，按日历期对齐
经营现金流CBLLCV
| Q4 25 | $-10.8M | — | ||
| Q3 25 | $-11.1M | $-5.7M | ||
| Q2 25 | $-7.5M | $-9.5M | ||
| Q1 25 | $-11.4M | — | ||
| Q3 24 | — | — |
自由现金流CBLLCV
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $-11.5M | $-5.7M | ||
| Q2 25 | $-7.6M | $-9.6M | ||
| Q1 25 | $-11.6M | — | ||
| Q3 24 | — | — |
自由现金流率CBLLCV
| Q4 25 | -44.2% | — | ||
| Q3 25 | -50.8% | -160.5% | ||
| Q2 25 | -35.9% | -289.0% | ||
| Q1 25 | -56.4% | — | ||
| Q3 24 | — | — |
资本支出强度CBLLCV
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.6% | 0.3% | ||
| Q2 25 | 0.3% | 2.1% | ||
| Q1 25 | 0.7% | — | ||
| Q3 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
CV
暂无分部数据
